GlassScriptPhysician profile
Andrew C Boulos
NPI 1689010100
$14,142.92
in general payments reported to CMS, 2019-2025
43 companies · $3,458 in 2025
The $3,458 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $385 · 2021: $1,205 · 2022: $1,589 · 2023: $5,182 · 2024: $1,534 · 2025: $3,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,854 · Consulting Fee: $3,200 · Travel and Lodging: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,854.25 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $1,118.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $5,591.58 | 2021-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Grifols USA, LLC | $1,148.08 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $1,119.10 | 2020-2025 | Breztri, Fasenra, Symbicort |
| Genzyme Corporation | $958.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.66 | 2020-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $609.64 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $608.90 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $435.39 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Inspire Medical Systems, INC. | $226.48 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $212.00 | 2023-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $206.55 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.67 | 2022-2025 | Glassia |
| Insmed, INC. | $198.27 | 2019-2025 | Arikayce |
| Baxter Healthcare | $194.10 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Merck Sharp & Dohme LLC | $154.54 | 2020-2025 | Winrevair |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $139.48 | 2022-2025 | Cresemba |
| Genentech USA, INC. | $138.45 | 2019-2025 | Tecentriq |
| Inari Medical, INC. | $132.15 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $129.09 | 2021-2025 | Tezspire, Tavneos |
| Pfizer INC. | $128.40 | 2020-2025 | |
| Abbvie INC. | $108.46 | 2021-2023 | Avycaz, Teflaro |
| Philips North America LLC | $99.98 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Electromed, INC. | $98.89 | 2022-2025 | Smartvest |
| Mylan Specialty L.P. | $88.64 | 2023-2024 | Yupelri |
| Gilead Sciences, INC. | $61.24 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $53.70 | 2023-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $52.44 | 2023-2024 | Lumryz |
| Pharming Healthcare, INC. | $46.88 | 2023 | Ruconest |
| Liquidia Technologies, INC. | $34.18 | 2025 | Yutrepia |
| Teva Pharmaceuticals USA, INC. | $30.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.85 | 2023 | Ultomiris |
| Viatris Specialty LLC | $24.38 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $22.15 | 2024 | Xacduro |
| Novartis Pharmaceuticals Corporation | $21.44 | 2023 | |
| Inogen, INC. | $20.68 | 2025 | |
| Allergan, INC. | $20.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 2022 | |
| Axsome Therapeutics, INC. | $17.46 | 2023 | Sunosi |
| Zoll Respicardia, INC. | $14.98 | 2023 | Remede System |
| Lilly USA, LLC | $14.80 | 2025 | Zepbound |
| Angiodynamics, INC. | $14.05 | 2025 | Angiovac |
| Mallinckrodt Hospital Products INC. | $12.87 | 2021 | |
| Intuitive Surgical, INC. | $12.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Boulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.